Sociedad Americana de Hirudoterapia

Direct thrombin inhibitors

Review published in Expert Opin Pharmacother (2003)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosFarmacología salivalKaplan KL · Expert opinion on pharmacotherapy, 2003

Abstract

This review deals with a newly-developed category of antithrombotic drugs - the direct thrombin inhibitors. These agents interact with thrombin and block its catalytic activity on fibrinogen, platelets and other substrates. Heparin and its derivatives (low molecular weight heparins and the active pentasaccharide) inhibit thrombin and/or other coagulation serine proteases indirectly via antithrombin, and the warfarin-type drugs interfere with the synthesis of the precursors of the coagulation serine proteases. The direct thrombin inhibitors approved for clinical use at present (lepirudin, desirudin, bivalirudin, argatroban) and another in the advanced clinical testing stage (melagatran/ximelagatran), are the subject of this review. The chemical structure; kinetics of thrombin inhibition; pharmacokinetics and clinical use of each of these is discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAntithrombinsArginineCoronary DiseaseHalf-LifeHirudinsHumansMetabolic Clearance RatePeptide FragmentsPipecolic AcidsRecombinant ProteinsSulfonamidesThrombin

Resumen

Foundational pharmacology review of direct thrombin inhibitors approved for clinical use: lepirudin, desirudin, bivalirudin, argatroban, plus melagatran/ximelagatran in development. Chemistry, kinetics, pharmacokinetics, and clinical use covered.

Por qué esto importa para la hirudoterapia

This review covers direct thrombin inhibitors — lepirudin, desirudin, bivalirudin, argatroban, and melagatran/ximelagatran — discussing their chemical structure, kinetics of thrombin inhibition, pharmacokinetics, and clinical use. The abstract describes these as antithrombotic agents that interact directly with thrombin and block its catalytic activity, contrasting them with indirect inhibitors (heparin derivatives) and warfarin-type drugs. For ASH's domain, the abstract itself does not mention leeches, hirudin, or any leech-derived connection, so a direct link to hirudotherapy or leech biology cannot be established from this text alone. Caveat: this is a pharmacology review with no original experimental data; it addresses pharmaceutical antithrombotic agents rather than leech therapy, and any connection to leech biology would require external knowledge not present in the abstract.

Citación

Direct thrombin inhibitors.

Kaplan KL · Expert opinion on pharmacotherapy, 2003

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsSalivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexBivalirudinHemostasisHirudinOtolaryngology

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.